Reuters logo
2 个月前
BRIEF-Epizyme says tazemetostat shows clinically meaningful activity
2017年5月18日 / 上午10点13分 / 2 个月前

BRIEF-Epizyme says tazemetostat shows clinically meaningful activity

1 分钟阅读

May 18 (Reuters) - Epizyme Inc:

* Epizyme announces path toward Tazemetostat registration in Epithelioid sarcoma and reports new clinical data to be presented at ASCO

* Says Tazemetostat demonstrates clinically meaningful activity in Epithelioid sarcoma

* Says based on discussions with fda, company has identified a path to submission for accelerated approval of Tazemetostat

* Says will target a new drug application (NDA) submission in 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below